Acumen Pharmaceuticals (ABOS) Earnings Date, Estimates & Call Transcripts $1.47 +0.09 (+6.52%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acumen Pharmaceuticals Earnings Summary Acumen Pharmaceuticals announced Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.48, which topped the consensus estimate of -$0.56 by $0.08. With a trailing EPS of -$1.94, Acumen Pharmaceuticals' earnings are expected to decrease next year, from ($1.56) to ($1.79) per share. Upcoming Q2 Earnings DateAug. 12Before Market OpensEstimatedConsensus EPS (May. 13) -$0.56 Actual EPS (May. 13) -$0.48 Beat By $0.08 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)SEC FilingABOS Upcoming EarningsAcumen Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 15, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Slide DeckFull Screen Slide DeckPowered by Get Acumen Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acumen Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataABOS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Acumen Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($1.56) EPSNext Year EPS Consensus Estimate ($1.79) EPS Acumen Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/12/2025(Estimated)--------5/13/2025Q1 2025-$0.56-$0.48+$0.08-$0.48--3/27/2025Q4 2024-$0.47-$0.62 -$0.15-$0.62--11/12/2024Q3 2024-$0.36-$0.50 -$0.14-$0.50--8/13/2024Q2 2024-$0.28-$0.34 -$0.06-$0.34--5/20/2024Q1 2024-$0.23-$0.25 -$0.02-$0.25--3/26/2024Q4 2023-$0.29-$0.29--$0.29--11/13/2023Q3 2023-$0.31-$0.24+$0.07-$0.24--8/8/2023Q2 2023-$0.36-$0.28+$0.08-$0.28-- Acumen Pharmaceuticals Earnings - Frequently Asked Questions When is Acumen Pharmaceuticals' earnings date? Acumen Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 12th, 2025 based off last year's report dates. Learn more on ABOS's earnings history. Did Acumen Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Acumen Pharmaceuticals (NASDAQ:ABOS) reported ($0.48) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.56) by $0.08. Learn more on analysts' earnings estimate vs. ABOS's actual earnings. How can I listen to Acumen Pharmaceuticals' earnings conference call? The conference call for Acumen Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Acumen Pharmaceuticals' conference call transcript? The conference call transcript for Acumen Pharmaceuticals' latest earnings report can be read online. Read Transcript How can I view Acumen Pharmaceuticals' earnings report? Acumen Pharmaceuticals' earnings report can be found in their filing with the SEC. View SEC filing How much profit does Acumen Pharmaceuticals generate each year? Acumen Pharmaceuticals (NASDAQ:ABOS) has a recorded net income of -$102.33 million. ABOS has generated -$1.94 earnings per share over the last four quarters. What is Acumen Pharmaceuticals' EPS forecast for next year? Acumen Pharmaceuticals' earnings are expected to decrease from ($1.56) per share to ($1.79) per share in the next year. More Earnings Resources from MarketBeat Related Companies Neumora Therapeutics Earnings Results Astria Therapeutics Earnings Results Tonix Pharmaceuticals Earnings Results Aura Biosciences Earnings Results Prothena Earnings Results Candel Therapeutics Earnings Results Monte Rosa Therapeutics Earnings Results Cartesian Therapeutics Earnings Results Foghorn Therapeutics Earnings Results Rocket Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Deckers Stock Recovers on Strong Earnings—More Upside Ahead?3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyCan Qualcomm Shock Wall Street With Its Q3 Earnings?T-Mobile Earnings Show You Why This Is a Stock to HoldAmerican Airlines Earnings Miss, But Bulls Aren’t Backing Off This page (NASDAQ:ABOS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts